Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Advanced
  • Structure search
  • List search
Wish Lists Wish Lists
Wish Lists Wish Lists
Wish Lists
Cart Cart
Cart Cart
Cart
Sign in
Sign in
For suppliers Contact us
Catalog of Screening CompoundsScreening LibrariesBuilding BlocksDrug Discovery ServicesCustom Chemistry
Advanced
  • Structure search
  • List search
Homepage > Company > Media > Pharma News > 2017 > Global coalition aims to outpace epidemics with new vaccines

Global coalition aims to outpace epidemics with new vaccines

A global coalition of governments, health specialists and philanthropists will launch a new plan on Thursday to "outsmart" future disease epidemics with a fund to prepare and create new vaccines.

Stung by the devastation of West Africa's 2014-2015 Ebola outbreak, which killed more than 11,300 people before an effective vaccine was developed, the coalition is aiming to ensure such deadly outbreaks can't happen again.

John-Arne Rottingen, interim chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI), said it is designed as "a global insurance policy against epidemic and pandemic threats".

 CEPI's founders used the World Economic Forum in Davos to announce its launch, with initial funding of $460 million from the governments of Germany, Japan and Norway, the Bill & Melinda Gates Foundation and the Wellcome Trust global health charity.

Bill Gates, co-chair of the Gates Foundation and a leading global health philanthropist, said recent major viral disease epidemics - Ebola and Zika - showed how the world "is tragically unprepared to detect local outbreaks and respond quickly enough to prevent them from becoming global pandemics".

"Without investments in research and development, we will remain unequipped when we face the next threat," he said. "The ability to rapidly develop and deliver vaccines when new unknown diseases emerge offers our best hope to outpace outbreaks, save lives and avert disastrous economic consequences."

The initial commitments mean CEPI has raised nearly half the $1 billion it needs for its first five years. It is now calling for proposals from researchers and companies who want to work on developing shots against its first target diseases - the Middle East Respiratory Syndrome (MERS), Lassa and Nipah viruses.

Rottingen said all these have shown the capacity to spread across borders and become fast-growing outbreaks causing death and illness. CEPI aims to drastically shorten the time it takes to make vaccines to protect against these and other viruses, which can emerge suddenly as global public health threats.

Jeremy Farrar, director of the Wellcome Trust, told Reuters CEPI aims to develop two vaccine candidates against each disease before any epidemic, so they are ready for rapid deployment in field trials if and when an outbreak starts.

He noted that with Ebola, despite huge international efforts to work faster, a vaccine was developed and validated as 100 percent protective only in the final months of the West Africa epidemic, after thousands had been infected and killed in Guinea, Sierra Leone and Liberia.

"This partnership is trying to make sure the horror of Ebola is not forgotten," he said. "There are moments in time that have to be seized."

CEPI is also backed by major pharmaceutical companies, the World Health Organization and the international health charity Médecins Sans Frontières (MSF).

Joanne Liu, head of MSF, welcomed the launch of CEPI but said price, safety and speed were crucial. "For new vaccines to be game changers, they must be developed and tested before outbreaks hit and made accessible and affordable for all communities in times of health crisis," she said.

Reporting by Kate Kelland; Editing by Mark Trevelyan

Davos, Switzerland | Wed Jan 18, 2017

Source: http://www.reuters.com/

 

Read also

FDA Approves Sandoz’ High-Concentration Version of Adalimumab Biosimilar, Hyrimoz
FDA Approves Sandoz’ High-Concentration Version of Adalimumab Biosimilar, Hyrimoz
Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab). ...
Arkansas Drug Manufacturer Draws FDA Warning Letter
Arkansas Drug Manufacturer Draws FDA Warning Letter
Dunagin Pharmaceuticals of Rogers, Ark., received an FDA warning letter for manufacturing drugs on the same equipment used to manufacture non-drug products and failing to test samples of product co...
FDA Approves Rezzayo, a Novel Echinocandin
FDA Approves Rezzayo, a Novel Echinocandin
The FDA approved rezafungin for injection (Rezzayo, Cidara Therapeutics/Melinta Therapeutics), a novel echinocandin, for the treatment of candidemia and invasive candidiasis in adults 18 years of a...
FDA Issues Warning Letter on Nyquil
FDA Issues Warning Letter on Nyquil
The FDA has accused Procter & Gamble (P&G) of submitting one ingredient list for Nyquil to the agency and using a different one for the over-the-counter product’s physical labeling. ...
preload
Catalog of Screening Compounds
Screening Libraries
  • Focused and Target Libraries
  • Active Reference Sets
  • Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
  • Custom Chemistry
  • Medicinal chemistry
  • In silico Drug Design (CADD)
  • Discovery Biology
  • Animal Models
  • Toxicology and Safety
  • ADME, DMPK
  • Chemistry, Manufacturing and Controls
Company
  • News & Media
  • Сareers
  • Delivery options
  • Contact us
  • For suppliers
  • Trends in discovery compounds
Contacts
Contact us
ChemDiv
10320 Camino Santa Fe, Suite B
San Diego CA92121-3103 USA
+1 858-794-4860
chemdiv@chemdiv.com
preload preload preload preload
Payment systems
Policies & Terms
©2023 ChemDiv     ChemistryOnDemand
Payment systems Payment systems
0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
  • Focused and Target Libraries
  • Active Reference Sets
  • Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers

Trends in discovery compounds